Structural optimization has led to the development of second- and third-generation ferrostatins, such as liproxstatin-1, SRS11-92, SRS16-86, and UAMC-3203, which exhibit enhanced stability and in vivo activity (414, 415)
These figures are in line with the other GLP-1 drugs such as semaglutide or tirzepatide that regularly hit $1,000 to $1,400 monthly at retail, though discounts and insurance can reduce the out-of-pocket cost
If you prefer an FDA-approved medication, please consult your personal healthcare provider
Patients are encouraged to report any suspected side effects to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk)
Well do this automatically for Ro patients when they log that they picked up their medication